Bayer eyes $1B-plus dermatology sale to fund Monsanto quest

Bayer sign

Bayer is closing in on a deal for agrichemicals giant Monsanto--and it’s reportedly mulling over a divestment that could help it get there.

The German drugmaker has brought on JPMorgan Chase to help it weigh options for its dermatology unit, Bloomberg’s sources say. And a sale of the portfolio--which includes eczema therapy Desonate and rosacea treatment Finacea--could bring in more than $1.1 billion, they told the news service.

The process is still in the early stages, though, and Bayer could of course still decide to hang onto the assets. If it did, it wouldn’t be the first time its Monsanto interest triggered divestment rumors that didn’t pan out: Back in May, when the pharma first approached Monsanto, analysts mused that Bayer want to unload its animal health offerings to help fund a takeover.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

If Bayer does settle on jettisoning its dermatology products, though, the business could prove attractive to the likes of Nestle’s Galderma, Allergan or Spain’s Almirall, according to Bloomberg’s sources.

Almirall and Allergan have both been in the M&A mix lately, with Almirall particularly in the hunt for skincare buys. As its CEO, Eduardo Sanchiz, told Reuters in July, “there are things” from Valeant’s portfolio “that could interest us” if the embattled drugmaker decides to sell. Allergan, meanwhile, recently tamped down buzz that it’s interested in multiple sclerosis specialist Biogen, but it has inked a pair of eyecare deals over the past month.

Private equity firms could also find Bayer’s dermatology division intriguing, the sources said.

Meanwhile, Bayer is pushing hard to seal a deal for Monsanto. Monday, it said negotiations with its cropcare rival had advanced and that it was willing to hike its bid past $65 billion; later in the week, Reuters reported that the two parties were “close” on price, with an agreement potentially coming within a week or two.

If Monsanto does agree to a buy, though, Bayer’s pharma unit could take a hit down the line, BMI Research’s Craig Smith has said. He sees the move “threatening the company’s key growth drivers--namely pharmaceuticals and consumer healthcare” and “diverting funds away from R&D activities” for those key business segments, he told in-PharmaTechnologist in May.

- get more from Bloomberg
- read more from Reuters on the Monsanto talks 

Related Articles:
Spain's Almirall eyes embattled Valeant's dermatology assets
Bayer's desired Monsanto buy could hurt its pharma, OTC ambitions: Analyst
Bayer's interest in Monsanto reignites talk of animal health sale

Read more on

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.